Liver fibrosis (LF) progresses more slowly after the elimination of the hepatitis C virus (HCV) by antiviral therapy. Liver biopsy is the gold standard for evaluating LF;however, it is invasive and can cause procedure-related complications. Therefore, non-invasive LF parameters are desired. Magnetic resonance elastography (MRE) is as accurate at assessing LF as liver biopsy. Mac-2 binding protein glycosylation isomer (M2BPGi) was reported to be a reliable serum marker for predicting LF and measuring liver function after antiviral therapy. HCV infections are relatively common among dialysis patients;however, the kinetics of the abovementioned non-invasive LF parameters in dialysis patients are unknown. Herein, we described the cases of 5 HCV-infected dialysis patients that were treated with direct-acting antivirals and underwent liver MRE and M2BPGi monitoring before and after treatment. Case 1 involved a 48-year-old male with liver cirrhosis (LC), who was treated with elbasvir and grazoprevir. Case 2 involved a 53-year-old male, who was treated with elbasvir and grazoprevir. Case 3 involved a 60-year-old male, who was treated with glecaprevir/pibrentasvir. Case 4 involved a 79-year-old female, who was treated with daclatasvir and asunaprevir. Case 5 involved a 78-year-old female, who was treated with ombitasvir, paritaprevir, and ritonavir. All patients achieved sustained virological responses at 12 and 24 weeks. The mean liver MRE values of the LC (n=1) and non-LC (n=2) patients were 5.6, and 2.25 and 2.9 kPa, respectively, and did not change after treatment. On the other hand, the M2BPGi levels of the LC and non-LC groups decreased from 2.59 to 1.51 C.O.I. and from 1.88 to 1.31 C.O.I., respectively, after treatment. Liver MRE was effective and accurate at assessing liver fibrosis in dialysis patients. Also, the M2BPGi levels of dialysis patients decreased after direct-acting antiviral treatment, as has been reported for non-dialysis patients.